What happened
Inhibrx Biosciences, Inc. (NASDAQ: INBX) said Chief Executive Officer and director Mark Lappe bought 10,000 shares from 2026-09-25 to 2026-09-28. The purchases were reported at prices from $98.87 to $101.70 per share. After the purchase, Lappe held 740,548 shares, and the filing ties the common stock to the Lappe Family Trust.
The form lists four Common Stock purchases. The detailed table lines show 3,324 shares at $98.8659, 2,176 at $99.5988, 1,500 at $98.8803 and 3,000 at $101.702. The earliest transaction date was 2026-09-25, and the latest was 2026-09-28.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares bought | 10,000 shares | SEC Form 4 | |
| Purchase price range | from $98.87 to $101.70 per share | SEC Form 4 | |
| Shares held after purchase | 740,548 shares | SEC Form 4 | |
| Purchase as share of pre-trade holdings | about 1.4% | Calculated from SEC Form 4 |
Why it matters
OptimistFi's case is that INBX is a financing- and data-dependent biotech option. This filing strengthens that case slightly because the chief executive added to his reported stake. The 10,000 shares were about 1.4% of the 730,548 shares he held before the trade, so the move is supportive but small.
The counterargument is that the purchase came in four transactions and the filing reports weighted-average prices, not one fixed entry price. That makes the report useful as ownership data, but it is not a full read on the company's clinical or financing path. The price range is better treated as a snapshot than as a precise single buy level.
The purchase size is modest relative to the pre-trade holding, but it still adds to an already large position. That is why the filing reads as supportive rather than decisive for the case.
What's next
This Form 4 sets a baseline for Mark Lappe's ownership after the September purchases. A later Form 4 showing more buying or selling would be the cleanest follow-up for investors watching whether this pattern continues. The filing itself gives investors a clean ownership baseline as of 2026-09-28.
If another filing shows continued buying, the insider signal would be easier to read. If later filings show no follow-through, this report remains a single data point on ownership, not a broader business milestone.
Sources
- SEC Form 4 — Reports Mark Lappe's purchases of 10,000 shares and his 740,548-share holding afterward.
Read the full OptimistFi thesis on Inhibrx Biosciences, Inc.: https://optimistfi.com/stocks/INBX
See what would break the Inhibrx Biosciences, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Inhibrx Biosciences, Inc. investment case, its status and the next test to watch live on the Inhibrx Biosciences, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
